Liz Foote – photo by Gus Cairns/AidsmapInjectable antiretroviral therapy will never reach its potential until people with unsuppressed viral loads can have it, the British HIV Association’s Autumn Conference heard last month in London.
Three presenters from the National HIV Nurses’ Association (NHIVNA) told the meeting that the criteria for injectable cabotegravir and rilpivirine were so strict that very few patients are eligible for them.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[Statement] MSF: Gilead stockholders: Demand Gilead sell HIV prevention drug to those who need it
-
Bhekisisa: In 2 years the Global Fund will cut South Africa’s grant by a quarter. In 8 years it will be gone
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.